Before a cancer therapeutic is selected for clinical development, scientists must fully characterize its mechanism of action, antitumor activity, and safety profile in preclinical animal studies. A key objective of these studies is also to optimize the schedule of drug administration in order to achieve maximum therapeutic efficacy with the least burden of adverse effects. For some cancer agents, continuous dosing is more efficacious compared to administration by immediate release methods, such as injections.

Since 1977, ALZET® Osmotic Pumps have been used in cancer studies as a dependable method for continuous delivery of experimental agents to unrestrained laboratory animals. ALZET pumps maximize efficacy by maintaining constant compound levels within their therapeutic range during prolonged treatment periods. Continuous delivery via ALZET pumps is also more efficient at reaching therapeutic effects with lower drug doses, thus minimizing drug toxicity and adverse effects. The pumps are easily connected to a catheter for delivery of agents directly into a specific target tissue, such as a tumor.
Cancer Research Applications

**Improve Efficacy and Lower Toxicity**

Many chemotherapeutic agents have a relatively narrow therapeutic index, defined as a small gap between the toxic and therapeutic doses. ALZET pumps deliver at continuous and controlled rates and can maintain drug levels in plasma or tissues within their therapeutic range, enabling the effects of therapeutic compounds to develop fully and reproducibly. As a result, therapeutic efficacy can be enhanced while also minimizing adverse effects.

**Use in Xenograft Models**

ALZET pumps have been used in numerous in vivo cancer models to study the antiproliferative effects of agents and dosing schedules. Because the pumps are self-contained and require no handling during the infusion period, they are well suited for use in murine xenograft models in immunocompromised species such as SCID and nude rodents. They have been useful in the study of carcinomas of the breast, prostate, liver, skin, stomach and lung (small cell); sarcomas such as fibrosarcoma, Leydig cell, osteosarcoma; lymphomas including Burkitt’s, EBV-related and EL4; and leukemias including myeloid and juvenile myelomonocytic, among others.

**Intratumoral Delivery**

ALZET pumps can easily be connected to a catheter to enable direct delivery of anti-cancer agents into tumors. This strategy has been shown to enhance the efficacy of some chemotherapeutics since regional tumor therapy is more efficient at reaching significant therapeutic effects with lower drug doses. Furthermore, drug levels in systemic circulation are decreased, minimizing drug exposure in sensitive organs and reducing potential side effects.

**Measurement of Cell Proliferation**

ALZET pumps have been used successfully to measure in vivo cell proliferation by continuous labeling with the base analog, 5-bromo-2’-deoxyuridine (BrdU). The pumps provide a continuous dose of the labeling agent over prolonged periods of time, which is essential for accurate measurement of slowly proliferating tissues, such as tumors. Because labeling occurs around-the-clock, results yield a true summation of the proliferative response for the entire labeling period. Continuous BrdU labeling using ALZET pumps has proven to be a more sensitive, reliable and convenient method for measuring chemically-induced cell proliferation.

**In Vivo Imaging Applications**

Bioluminescence imaging (BLI) is a useful experimental technique for in vivo imaging of small animals. It is a powerful tool for studying and monitoring ongoing biological processes (i.e., tumor growth) over time and in the same animal. ALZET pumps are increasingly being used in BLI studies as an effective means to facilitate steady-state delivery of bioluminescent substrates, such as luciferin. The pumps provide reliable and prolonged substrate delivery, thus eliminating repetitive injections and ensuring accurate detection of in vivo bioluminescence. ALZET pumps can be easily adapted for compatibility with BLI equipment.

**Humanized Mouse Models**

With the introduction of new, highly immunodeficient mouse strains (i.e., NOD/SCID, NSG), ALZET pumps are increasingly used in cancer studies with humanized mouse models. Their automatic operation, small size and simple design make them an ideal infusion system for chronic dosing studies in these species. They offer a convenient and reliable alternative to repetitive injections. No researcher intervention is required during infusion, and animal handling is kept to a minimum to reduce the risk of infection and stress.

**Chronic Delivery**

Chronic administration may be necessary to evaluate the long-term efficacy of anti-cancer agents in vivo. ALZET pumps offer a reliable and convenient alternative to frequent injections for chronic dosing of lab animals. Steady-state levels of therapeutic agents can be maintained in tissues or plasma for up to six weeks with a single pump, and the treatment duration can be extended for multiple months through serial implantation.
Selecting an Optimum Vehicle

The criteria for selecting a vehicle for ALZET pump infusion should include the solubility of the test compound, tissue compatibility, pH considerations for compound stability, and sterility. For many compounds soluble in aqueous media, Ringer’s solution is an appropriate vehicle since it is sterile, particle- and pyrogen-free, and non-irritating.

Many anti-cancer agents, especially small molecule therapeutics, are poorly soluble in aqueous vehicles due to their hydrophobic nature. For successful delivery, such compounds must be dissolved in a non-aqueous vehicle that is compatible with the pump reservoir material and effective at preventing compound precipitation during the entire dosing period. Researchers at Elan Pharmaceuticals and Pharmacyclics Inc. reported the development of a suitable solvent composition for dissolving poorly soluble compounds for preclinical studies using ALZET pumps.

Among various solvents investigated, a vehicle formulation containing 25% PEG 300, 25% Cremophor ELP, 25% glycofurol, 15% ethanol, and 10% propylene glycol was most effective at solubilizing two investigational compounds (ELND006 and ELN 481594) with poor aqueous solubility. This formulation was fully compatible with the ALZET pump reservoir material, and the compounds remained soluble and chemically stable throughout the administration period. Furthermore, it effectively prevented compound crystallization when in contact with an aqueous environment at the site of its release, such as in vitro during priming of the pump or in vivo at the site of pump implantation.


The power of continuous delivery

Injections can result in great variations in serum and tissue concentrations. Immediately after injection, compound concentrations commonly exceed effective levels, resulting in overdosing and toxicity. Rapid clearance causes periods between injections wherein the compound is absent from serum and tissues, resulting in underdosing and lack of drug effect. ALZET pumps deliver compound solutions at controlled and predictable rates, ensuring that constant and optimum levels of test agents are maintained throughout the study duration.

Cancer Research Publications

Therapeutic antibodies, enzyme inhibitors, angiogenesis modulators, cytokines, and chemotherapeutics are all examples of agents that have been successfully delivered via ALZET pumps. Below is a list of agents used in cancer research publications recently added to the ALZET bibliography. Contact us to request citations specific to your research interest.

<table>
<thead>
<tr>
<th>Agent</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone</td>
<td>Androgen</td>
</tr>
<tr>
<td>Angiotensin II</td>
<td>Peptide</td>
</tr>
<tr>
<td>CVT2584</td>
<td>CDK2 Inhibitor</td>
</tr>
<tr>
<td>Norepinephrine</td>
<td>Catecholamine</td>
</tr>
<tr>
<td>ICI-118551</td>
<td>β2 Adrenergic Receptor Inhibitor</td>
</tr>
<tr>
<td>JQ1</td>
<td>Bromodomain Containing 4 Inhibitor</td>
</tr>
<tr>
<td>PENAO</td>
<td>Anti-tumor Metabolic Compound</td>
</tr>
<tr>
<td>Oxytocin</td>
<td>Neuropeptide Hormone</td>
</tr>
<tr>
<td>Dasatinib</td>
<td>Tyrosine Kinase Inhibitor</td>
</tr>
<tr>
<td>YM-155</td>
<td>Survivin Inhibitor</td>
</tr>
<tr>
<td>Aquashield 1</td>
<td>Water-soluble Ligand</td>
</tr>
<tr>
<td>Handle Region Peptide</td>
<td>(Pro)Renin Receptor Antagonist</td>
</tr>
<tr>
<td>123 I-MAPi</td>
<td>PARP1 Inhibitor Radiolabeled with Auger- and γ-emitting Iodine Isotope</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>Selective Estrogen Receptor Modulator</td>
</tr>
<tr>
<td>Perampanel</td>
<td>AMPA Receptor Antagonist</td>
</tr>
<tr>
<td>IL-31, recombinant mouse</td>
<td>Proinflammatory Cytokine</td>
</tr>
<tr>
<td>GDF-15, recombinant mouse</td>
<td>Divergent TGF-β Superfamily Cytokine</td>
</tr>
</tbody>
</table>
What Leading Cancer Researchers Are Saying

<table>
<thead>
<tr>
<th>ALZET Benefit</th>
<th>Article Quote</th>
</tr>
</thead>
</table>
| Effective delivery  | “Ang II was administered by an ALZET osmotic pump...which could release Ang II continuously, homogeneously and stably; avoid stress due to repeated administration; and protect the short half-life of the drug.”  
| Improve efficacy    | “Continuous infusion substantially increased efficacy of LR compared to bolus dose administration.”  
| Targeted delivery   | “Localized BEV delivery by Alzet micro-osmotic pumps is more effective in reducing tumor size and tumor cell infiltration when compared with systemic administration”  
Liu et al. OncoTargets and Therapy 2018;11:2673-2683 |
| Reduce toxicity     | “The mini-osmotic pump provides drug treatment directly to the brain and also bypasses the liver, thereby achieving the desired drug concentration in the glioma microenvironment while avoiding the use of high drug doses.”  
| Reduce stress       | “Because repeated surgery introduces stress and pain that may impact the survival of the experimental animals, we opted for the convection-enhanced delivery (CED) strategy using an Alzet osmotic pump to deliver a continuous supply of the nano RNAi combination...this strategy had been successful in our previous application in a rodent model of CNS disorders”  
Yu et al. Proceedings of the National Academy of Sciences of the United States of America 2017;114(30):E6147-E6156 |
| Stable plasma levels| “Pilot experiments...confirmed that MPs [ALZET Minipumps] could provide relatively constant everolimus concentrations in the plasma.”  

How does it work?
ALZET pumps are composed of 3 concentric layers: the drug reservoir, the osmotic layer, and an outer, rate-controlling, semipermeable membrane. Once implanted, the pump begins to absorb water through the outer, semipermeable membrane. The water entering the pump hydrates and expands the osmotic layer, compressing the flexible, impermeable reservoir. As a result, test solution is released via the exit port at a controlled, predetermined rate.

ALZET Osmotic Pumps are available in 3 sizes and a range of flow rates and durations to meet your research needs

Customer Service  
toll-free: 877.922.5938  
phone: 408.761.4542  
alzetcs@durect.com

Technical Support  
toll-free: 800.692.2990  
phone: 408.761.3630  
alzet@durect.com

Mailing  
10260 Bubb Road  
Cupertino, CA 95014  
www.alzet.com